Cline Scientific AB Series B
Cline Scientific AB (publ), a life science company, develops cancer diagnostics and stem cell therapies in Sweden. The company's clinical-stage projects include StemCART, a stem cell therapy for joint repair; and CellRACE, a cancer diagnostic to predict metastasis. It also develops nanotechnology based products for work within Life Sciences. The company has collaboration with Sahlgrenska that dev… Read more
Cline Scientific AB Series B (CLINE-B) - Total Assets
Latest total assets as of December 2023: Skr22.72 Million SEK
Based on the latest financial reports, Cline Scientific AB Series B (CLINE-B) holds total assets worth Skr22.72 Million SEK as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cline Scientific AB Series B - Total Assets Trend (2012–2023)
This chart illustrates how Cline Scientific AB Series B’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cline Scientific AB Series B - Asset Composition Analysis
Current Asset Composition (December 2023)
Cline Scientific AB Series B's total assets of Skr22.72 Million consist of 15.2% current assets and 84.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 14.7% |
| Accounts Receivable | Skr104.66K | 0.5% |
| Inventory | Skr-104.66K | -0.5% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr2.01 Million | 8.9% |
| Goodwill | Skr-17.23 Million | -75.9% |
Asset Composition Trend (2012–2023)
This chart illustrates how Cline Scientific AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cline Scientific AB Series B's current assets represent 15.2% of total assets in 2023, a decrease from 23.5% in 2012.
- Cash Position: Cash and equivalents constituted 14.7% of total assets in 2023, down from 19.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up -67.0% of total assets, a decrease from 73.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 8.9% of total assets.
Cline Scientific AB Series B Competitors by Total Assets
Key competitors of Cline Scientific AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cline Scientific AB Series B - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cline Scientific AB Series B generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cline Scientific AB Series B is currently not profitable relative to its asset base.
Cline Scientific AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.91 | 7.52 | 9.48 |
| Quick Ratio | 1.91 | 7.99 | 11.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr1.65 Million | Skr 3.54 Million | Skr 2.85 Million |
Cline Scientific AB Series B - Advanced Valuation Insights
This section examines the relationship between Cline Scientific AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.15 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 20.7% |
| Total Assets | Skr22.72 Million |
| Market Capitalization | $188.96K USD |
Valuation Analysis
Below Book Valuation: The market values Cline Scientific AB Series B's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cline Scientific AB Series B's assets grew by 20.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cline Scientific AB Series B (2012–2023)
The table below shows the annual total assets of Cline Scientific AB Series B from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | Skr22.72 Million | +20.75% |
| 2022-12-31 | Skr18.82 Million | +2.71% |
| 2021-12-31 | Skr18.32 Million | +64.76% |
| 2020-12-31 | Skr11.12 Million | +17.16% |
| 2019-12-31 | Skr9.49 Million | +64.09% |
| 2018-12-31 | Skr5.78 Million | -6.69% |
| 2017-12-31 | Skr6.20 Million | +2.51% |
| 2016-12-31 | Skr6.05 Million | -31.28% |
| 2015-12-31 | Skr8.80 Million | +438.92% |
| 2013-12-31 | Skr1.63 Million | +13.07% |
| 2012-12-31 | Skr1.44 Million | -- |